PMHNP Certification Exam 2026-2027
Questions with Detailed Explanations
Updated for DSM-5-TR, Latest
Psychopharmacology, and Board Exam
Blueprint
Section 1: Psychopharmacology – Pharmacokinetics & Pharmacodynamics
Question 1
When many answers on an examination are remarkably similar, they are usually
______.
A. incorrect
B. correct
C. indicating a pattern
D. distractors
Answer: A. incorrect
Explanation: In examination construction, unusually similar answer choices are
typically designed as incorrect options (distractors) to test the examinee's ability to
distinguish subtle differences.
Question 2
A patient asks the PMHNP to explain the difference between pharmacokinetics and
pharmacodynamics. Which response is most accurate?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what
the body does to the drug
B. Both terms describe the same process of drug metabolism in the liver
C. Pharmacokinetics is what the body does to the drug; pharmacodynamics is what
the drug does to the body
D. Pharmacokinetics refers to drug absorption only; pharmacodynamics refers to
drug excretion only
Answer: C. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
Explanation: Pharmacokinetics = ADME (absorption, distribution, metabolism,
,excretion). Pharmacodynamics = drug’s effects on the body (receptor binding,
response).
Question 3
A drug that binds to a receptor and activates a biological response by opening an
ion channel is best described as:
A. Partial agonist
B. Inverse agonist
C. Antagonist
D. Agonist
Answer: D. Agonist
Explanation: Full agonists produce maximal activation of receptors, including ion
channel opening. Partial agonists produce submaximal activation; inverse
agonists produce opposite effects; antagonists block without activation.
Question 4
A patient smokes two packs of cigarettes daily and is prescribed clozapine. The
PMHNP understands that smoking will most likely:
A. Increase clozapine serum levels due to enzyme inhibition
B. Decrease clozapine therapeutic levels due to enzyme induction
C. Have no effect on clozapine metabolism
D. Increase the risk of agranulocytosis
Answer: B. Decrease clozapine therapeutic levels due to enzyme induction
Explanation: Smoking induces CYP1A2, increasing clozapine metabolism.
Smokers often require higher doses; smoking cessation requires dose reduction to
prevent toxicity.
Question 5
Which cytochrome P450 enzyme is most associated with tobacco induction when
treating a patient with clozapine?
A. CYP2D6
B. CYP1A2
C. CYP2C19
D. CYP3A4
Answer: B. CYP1A2
Explanation: Tobacco smoke contains polycyclic aromatic hydrocarbons that
induce CYP1A2, the primary enzyme for clozapine and olanzapine metabolism.
,Question 6
A patient on fluoxetine (an SSRI) is prescribed tramadol for pain. The PMHNP
should be concerned about:
A. Serotonin syndrome
B. Hypertensive crisis
C. Nephrotoxicity
D. Prolonged QT interval
Answer: A. Serotonin syndrome
Explanation: Tramadol has serotonergic properties; combined with an SSRI
increases risk of serotonin syndrome (agitation, hyperreflexia, clonus, fever).
Question 7
Which antidepressant has the highest risk of discontinuation syndrome due to its
short half-life?
A. Fluoxetine
B. Sertraline
C. Paroxetine
D. Citalopram
Answer: C. Paroxetine
Explanation: Paroxetine has the shortest half-life (~21 hours) among SSRIs and
lacks active metabolites, leading to a high risk of withdrawal (dizziness, nausea,
“brain zaps”).
Question 8
A patient taking valproate (Depakote) is planning to become pregnant. The
PMHNP should counsel that valproate is associated with:
A. Low risk of neural tube defects
B. High risk of neural tube defects (spina bifida) and lower IQ in offspring
C. No teratogenic risk
D. Risk of cleft palate only
Answer: B. High risk of neural tube defects (spina bifida) and lower IQ in
offspring
Explanation: Valproate has the highest teratogenic risk among mood stabilizers
(neural tube defects, cardiac malformations, cognitive impairment). Alternative
agents are recommended in pregnancy.
, Question 9
A patient on lithium develops coarse tremor, ataxia, and confusion. Serum lithium
level is 2.2 mEq/L. These symptoms indicate:
A. Therapeutic effect
B. Mild toxicity
C. Moderate to severe toxicity
D. Allergic reaction
Answer: C. Moderate to severe toxicity
*Explanation: Lithium toxicity levels: 1.5-2.0 mEq/L = moderate (nausea, coarse
tremor); >2.0 = severe (ataxia, confusion, seizures, coma).*
Question 10
The major route of lithium excretion is:
A. Hepatic metabolism
B. Renal (glomerular filtration)
C. Sweat glands
D. Lungs
Answer: B. Renal (glomerular filtration)
Explanation: Lithium is excreted unchanged by the kidneys. Anything that reduces
GFR (dehydration, NSAIDs, renal disease) increases toxicity risk.
Section 2: Mood Disorders & Antidepressants
Question 11
A patient with MDD fails to improve after 6 weeks of sertraline 150 mg/day.
Which is the most appropriate next step?
A. Increase to 200 mg/day
B. Switch to bupropion
C. Augment with aripiprazole
D. Evaluate adherence and consider switching or augmenting
Answer: D. Evaluate adherence and consider switching or augmenting
Explanation: After adequate trial (4-8 weeks at therapeutic dose), non-response
requires re-evaluation. Augmentation (aripiprazole, bupropion) or switching (to
another SSRI, SNRI, or mirtazapine) are evidence-based.
Questions with Detailed Explanations
Updated for DSM-5-TR, Latest
Psychopharmacology, and Board Exam
Blueprint
Section 1: Psychopharmacology – Pharmacokinetics & Pharmacodynamics
Question 1
When many answers on an examination are remarkably similar, they are usually
______.
A. incorrect
B. correct
C. indicating a pattern
D. distractors
Answer: A. incorrect
Explanation: In examination construction, unusually similar answer choices are
typically designed as incorrect options (distractors) to test the examinee's ability to
distinguish subtle differences.
Question 2
A patient asks the PMHNP to explain the difference between pharmacokinetics and
pharmacodynamics. Which response is most accurate?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what
the body does to the drug
B. Both terms describe the same process of drug metabolism in the liver
C. Pharmacokinetics is what the body does to the drug; pharmacodynamics is what
the drug does to the body
D. Pharmacokinetics refers to drug absorption only; pharmacodynamics refers to
drug excretion only
Answer: C. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body
Explanation: Pharmacokinetics = ADME (absorption, distribution, metabolism,
,excretion). Pharmacodynamics = drug’s effects on the body (receptor binding,
response).
Question 3
A drug that binds to a receptor and activates a biological response by opening an
ion channel is best described as:
A. Partial agonist
B. Inverse agonist
C. Antagonist
D. Agonist
Answer: D. Agonist
Explanation: Full agonists produce maximal activation of receptors, including ion
channel opening. Partial agonists produce submaximal activation; inverse
agonists produce opposite effects; antagonists block without activation.
Question 4
A patient smokes two packs of cigarettes daily and is prescribed clozapine. The
PMHNP understands that smoking will most likely:
A. Increase clozapine serum levels due to enzyme inhibition
B. Decrease clozapine therapeutic levels due to enzyme induction
C. Have no effect on clozapine metabolism
D. Increase the risk of agranulocytosis
Answer: B. Decrease clozapine therapeutic levels due to enzyme induction
Explanation: Smoking induces CYP1A2, increasing clozapine metabolism.
Smokers often require higher doses; smoking cessation requires dose reduction to
prevent toxicity.
Question 5
Which cytochrome P450 enzyme is most associated with tobacco induction when
treating a patient with clozapine?
A. CYP2D6
B. CYP1A2
C. CYP2C19
D. CYP3A4
Answer: B. CYP1A2
Explanation: Tobacco smoke contains polycyclic aromatic hydrocarbons that
induce CYP1A2, the primary enzyme for clozapine and olanzapine metabolism.
,Question 6
A patient on fluoxetine (an SSRI) is prescribed tramadol for pain. The PMHNP
should be concerned about:
A. Serotonin syndrome
B. Hypertensive crisis
C. Nephrotoxicity
D. Prolonged QT interval
Answer: A. Serotonin syndrome
Explanation: Tramadol has serotonergic properties; combined with an SSRI
increases risk of serotonin syndrome (agitation, hyperreflexia, clonus, fever).
Question 7
Which antidepressant has the highest risk of discontinuation syndrome due to its
short half-life?
A. Fluoxetine
B. Sertraline
C. Paroxetine
D. Citalopram
Answer: C. Paroxetine
Explanation: Paroxetine has the shortest half-life (~21 hours) among SSRIs and
lacks active metabolites, leading to a high risk of withdrawal (dizziness, nausea,
“brain zaps”).
Question 8
A patient taking valproate (Depakote) is planning to become pregnant. The
PMHNP should counsel that valproate is associated with:
A. Low risk of neural tube defects
B. High risk of neural tube defects (spina bifida) and lower IQ in offspring
C. No teratogenic risk
D. Risk of cleft palate only
Answer: B. High risk of neural tube defects (spina bifida) and lower IQ in
offspring
Explanation: Valproate has the highest teratogenic risk among mood stabilizers
(neural tube defects, cardiac malformations, cognitive impairment). Alternative
agents are recommended in pregnancy.
, Question 9
A patient on lithium develops coarse tremor, ataxia, and confusion. Serum lithium
level is 2.2 mEq/L. These symptoms indicate:
A. Therapeutic effect
B. Mild toxicity
C. Moderate to severe toxicity
D. Allergic reaction
Answer: C. Moderate to severe toxicity
*Explanation: Lithium toxicity levels: 1.5-2.0 mEq/L = moderate (nausea, coarse
tremor); >2.0 = severe (ataxia, confusion, seizures, coma).*
Question 10
The major route of lithium excretion is:
A. Hepatic metabolism
B. Renal (glomerular filtration)
C. Sweat glands
D. Lungs
Answer: B. Renal (glomerular filtration)
Explanation: Lithium is excreted unchanged by the kidneys. Anything that reduces
GFR (dehydration, NSAIDs, renal disease) increases toxicity risk.
Section 2: Mood Disorders & Antidepressants
Question 11
A patient with MDD fails to improve after 6 weeks of sertraline 150 mg/day.
Which is the most appropriate next step?
A. Increase to 200 mg/day
B. Switch to bupropion
C. Augment with aripiprazole
D. Evaluate adherence and consider switching or augmenting
Answer: D. Evaluate adherence and consider switching or augmenting
Explanation: After adequate trial (4-8 weeks at therapeutic dose), non-response
requires re-evaluation. Augmentation (aripiprazole, bupropion) or switching (to
another SSRI, SNRI, or mirtazapine) are evidence-based.
